Praxis Precision Medicines, Inc.
PRAX · XNASCIK 1689548fmd_061WJWP3HZ04WKE3RZTSGDASF7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 2 | 9 | 0 |
| Realized investment gains (losses) | – | – | – | – | 0 | 0 | 0 |
| Research and development | 30 | 45 | 120 | 155 | 87 | 152 | 267 |
| Total operating expenses | 36 | 62 | 167 | 215 | 129 | 209 | 326 |
| Operating income | (36) | (62) | (167) | (215) | (126) | (200) | (326) |
| Other non-operating income (expense) | 0 | 0 | 0 | 1 | 3 | 17 | 23 |
| Income before taxes | (36) | (62) | (167) | – | (123) | (183) | (303) |
| Income tax expense | (0) | (0) | 0 | – | – | – | 0 |
| Net income from continuing operations | (36) | (62) | (167) | – | – | – | (303) |
| Net income | (36) | (62) | (167) | (214) | (123) | (183) | (303) |
| Net income to common shareholders | (41) | (70) | (167) | – | – | – | – |